Citations

Mayo Clinic

Showing 10 of 108551 citations.

Segond Fractures Can Be Identified With Excellent Accuracy Utilizing Deep Learning on Anteroposterior Knee Radiographs
Oeding, Jacob F. , Pareek, Ayoosh , Kunze, Kyle N. , Nwachukwu, Benedict U. , Greditzer, Harry G. , Camp, Christopher L. , Kelly, Bryan T. , Pearle, Andrew D. , Registry, HSS ACL Reconstruction, Camp, Christopher L. , Oeding, Jacob F , Ranawat, Anil S. , Williams, Riley J. , Registry, HSS ACL Reconstruction

Arthroscopy, Sports Medicine, and Rehabilitation | April 8, 2024 | Volume: 6 | Issue: 3 | Pages: No page available

10.1016/j.asmr.2024.100940 | PMID 39006790 Get It

Purpose To develop a deep learning model for the detection of Segond fractures on anteroposterior (AP) knee radiographs and to compare model performance to that of trained human experts. Methods AP knee radiographs were retrieved from the Hospital for Special Surgery ACL Registry, which enrolled patients between 2009 and 2013. All images corresponded to patients who underwent anterior cruciate ligament reconstruction by 1 of 23 surgeons included in the registry data. Images were categorized into 1 of 2 classes based on radiographic evidence of a Segond fracture and manually annotated. Seventy percent of the images were used to populate the training set, while 20% and 10% were reserved for the validation and test sets, respectively. Images from the test set were used to compare model performance to that of expert human observers, including an orthopaedic surgery sports medicine fellow and a fellowship‐trained orthopaedic sports medicine surgeon with over 10 years of experience. Results A total of 324 AP knee radiographs were retrieved, of which 34 (10.4%) images demonstrated evidence of a Segond fracture. The overall mean average precision (mAP) was 0.985, and this was maintained on the Segond fracture class (mAP = 0.978, precision = 0.844, recall = 1). The model demonstrated 100% accuracy with perfect sensitivity and specificity when applied to the independent testing set and the ability to meet or exceed human sensitivity and specificity in all cases. Compared to an orthopaedic surgery sports medicine fellow, the model required 0.3% of the total time needed to evaluate and classify images in the independent test set. Conclusions A deep learning model was developed and internally validated for Segond fracture detection on AP radiographs and demonstrated perfect accuracy, sensitivity, and specificity on a small test set of radiographs with and without Segond fractures. The model demonstrated superior performance compared with expert human observers. Clinical Relevance Deep learning can be used for automated Segond fracture identification on radiographs, leading to improved diagnosis of easily missed concomitant injuries, including lateral meniscus tears. Automated identification of Segond fractures can also enable large‐scale studies on the incidence and clinical significance of these fractures, which may lead to improved management and outcomes for patients with knee injuries.
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer
Yaeger, Rona , Uboha, Nataliya V. , Pelster, Meredith S. , Bekaii‐Saab, Tanios , Barve, Minal , Saltzman, Joel , Sabari, Joshua K. , Peguero, Julio A. , Paulson, Andrew Scott , Jänne, Pasi A. , Anderes, Kenna , Velastegui, Karen , Yan, Xiaohong , Der‐Torossian, Hirak , Bekaii-Saab, Tanios S , Cruz-Correa, Marcia , Anderes, Kenna , Velastegui, Karen , Yan, Xiaohong , Der-Torossian, Hirak , Klempner, Samuel J , Kopetz, Scott , Cruz‐Correa, Marcia , Klempner, Samuel J. , Kopetz, Scott

Cancer Discovery | April 8, 2024 | Volume: 14 | Issue: 6 | Pages: 982-993

10.1158/2159-8290.cd-24-0217 | PMID 38587856 Get It

Abstract Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4
Trends and Disparities in Valvular Heart Disease Mortality in the United States From 1999 to 2020
Tan, Min Choon , Yeo, Yong Hao , San, Boon Jian , Suleiman, Addi, Lee, Justin Z. , Chatterjee, Arka , Sell‐Dottin, Kristen , Sweeney, John P., Fortuin, F. David , Lee, Kwan , Sell-Dottin, Kristen A , Lee, Kwan S , Yeo, Yong Hao , Fortuin, Floyd David , Tan, Min C

Journal of the American Heart Association | April 8, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.030895 | PMID 38587138 Get It

Background Percutaneous heart valve procedures have been increasingly performed over the past decade, yet real‐world mortality data on valvular heart disease (VHD) in the United States remain limited. Methods and Results We queried the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research database among patients ≥15 years old from 1999 to 2020. VHD and its subtypes were listed as the underlying cause of death. We calculated age‐adjusted mortality rate (AAMR) per 100 000 individuals and determined overall trends by estimating the average annual percent change using the Joinpoint regression program. Subgroup analyses were performed based on demographic and geographic factors. In the 22‐year study, there were 446 096 VHD deaths, accounting for 0.80% of all‐cause mortality (56 014 102 people) and 2.38% of the total cardiovascular mortality (18 759 451 people). Aortic stenosis recorded the highest mortality of VHD‐related death in both male (109 529, 61.74%) and female (166 930, 62.13%) populations. The AAMR of VHD has declined from 8.4 (95% CI, 8.2–8.5) to 6.6 (95% CI, 6.5–6.7) per 100 000 population. Similar decreasing AAMR trends were also seen for the VHD subtypes. Men recorded higher AAMR for aortic stenosis and aortic regurgitation, whereas women had higher AAMR for mitral stenosis and mitral regurgitation. Mitral regurgitation had the highest change in average annual percent change in AAMR. Conclusions The mortality rate of VHD among the US population has declined over the past 2 decades. This highlights the likely efficacy of increasing surveillance and advancement in the management of VHD, resulting in improved outcomes.
An adult with cystathionine beta-synthase deficiency, camptodactyly-arthropathy-coxa vara-pericarditis syndrome, and deafness: A case report
Donis, Karina Carvalho , Kalil, Marco Antônio Baptista, Poswar, Fabiano de Oliveira , Kohem, Charles Lubianca , Poloni, Soraia , Borsatto, Taciane , Pinheiro, Franciele Cabral , Schwartz, Ida Vanessa Döederlein , de Oliveira Poswar, Fabiano , Pinheiro, Franciele Cabral , Schwartz, Ida Vanessa Doederlein , Kok, Fernando , Vairo, Filippo Pinto e

Genetics and Molecular Biology | April 8, 2024 | Volume: 47 | Issue: 1 | Pages: No page available

10.1590/1678-4685-gmb-2022-0335 | PMID 38593426 Get It

Racial Disparities in Early-Stage NSCLC Treatment: A Call for Action
Pellini, Bruna , Chaudhuri, Aadel A. , Pellini, Bruna

Cancer Epidemiology, Biomarkers & Prevention | April 8, 2024 | Volume: 33 | Issue: 6 | Pages: 769-770

10.1158/1055-9965.epi-24-0339 | PMID 38587480 Get It

Abstract Non–small cell lung cancer (NSCLC) is associated with a 5-year survival rate of only 28%; however, when caught at an early stage, it can be cured with surgery or stereotactic body radiotherapy (SBRT). Unfortunately, racial disparities may result in limited access to care for some patients. Liu and colleagues analyzed 64,999 cases of early-stage NSCLC treated between 2005 and 2017 from the Florida Cancer Registry and showed that Black patients had 36% lower odds of receiving curative-intent surgery compared with their White counterparts. This study highlights significant racial disparities in treatment patterns that must be addressed urgently. See related article by Liu and colleagues, Cancer Epidemiol Biomarkers Prev 2024;33:489–99
Ultrasound and magnetic resonance imaging features of fetal urogenital anomalies: A pictorial essay
Moradi, Behnaz , Golezar, Mohammad Hossein , Ardestani, Reihaneh Mortazavi , Hassanzadeh, Sara, Jannatdoust, Payam , Banihashemian, Masoumeh , Batavani, Nasim

Congenital Anomalies | April 8, 2024 | Volume: 64 | Issue: 3 | Pages: 70-90

10.1111/cga.12568 | PMID 38586935 Get It

AbstractThis pictorial essay focuses on ultrasound (US) and magnetic resonance imaging (MRI) features of fetal urogenital anomalies. Fetal urogenital malformations account for 30%–50% of all anomalies discovered during pregnancy or at birth. They are usually detected by fetal ultrasound exams. However, when ultrasound data on their characteristics is insufficient, MRI is the best option for detecting other associated anomalies. The prognosis highly depends on their type and whether they are associated with other fetal abnormalities.
Type II mast cells in mast cell leukemia: Uncommon yet clinically significant
Chen, Constance P. , Chen, Dong , Chen, Dong

eJHaem | April 8, 2024 | Volume: 5 | Issue: 2 | Pages: 412-413

10.1002/jha2.893 | PMID 38633112 Get It

Rates of Recurrent Intestinal Metaplasia and Dysplasia After Successful Endoscopic Therapy of Barrett's Neoplasia by Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection and Ablation: A Large North American Multicenter Cohort
Vantanasiri, Kornpong , Joseph, Abel , Sachdeva, Karan , Goyal, Rohit , Garg, Nikita , Adoor, Dayyan , Kamboj, Amrit K. , Codipilly, Don C. , Leggett, Cadman L. , Wang, Kenneth K. , Harmsen, William S. , Hayat, Umar , Chak, Amitabh , Bhatt, Amit , Iyer, Prasad G. , Codipilly, Don Chamil , Leggett, Cadman L , Bhatt, Amit , Vantanasiri, Kornpong

American Journal of Gastroenterology | April 8, 2024 | Volume: 119 | Issue: 9 | Pages: 1831-1840

10.14309/ajg.0000000000002798 | PMID 38587280 Get It

INTRODUCTION: Endoscopic eradication therapy (EET) combining endoscopic resection (ER) with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) followed by ablation is the standard of care for the treatment of dysplastic Barrett's esophagus (BE). We have previously shown comparable rates of complete remission of intestinal metaplasia (CRIM) with both approaches. However, data comparing recurrence after CRIM are lacking. We compared rates of recurrence after CRIM with both techniques in a multicenter cohort. METHODS: Patients undergoing EET achieving CRIM at 3 academic institutions were included. Demographic and clinical data were abstracted. Outcomes included rates and predictors of any BE and dysplastic BE recurrence in the 2 groups. Cox-proportional hazards models and inverse probability treatment weighting (IPTW) analysis were used for analysis. RESULTS: A total of 621 patients (514 EMR and 107 ESD) achieving CRIM were included in the recurrence analysis. The incidence of any BE (15.7, 5.7 per 100 patient-years) and dysplastic BE recurrence (7.3, 5.3 per 100 patient-years) were comparable in the EMR and ESD groups, respectively. On multivariable analyses, the chances of BE recurrence were not influenced by ER technique (hazard ratio 0.87; 95% confidence interval 0.51–1.49; P = 0.62), which was also confirmed by IPTW analysis (ESD vs EMR: hazard ratio 0.98; 95% confidence interval 0.56–1.73; P = 0.94). BE length, lesion size, and history of cigarette smoking were independent predictors of BE recurrence. DISCUSSION: Patients with BE dysplasia/neoplasia achieving CRIM, initially treated with EMR/ablation, had comparable recurrence rates to ESD/ablation. Randomized trials are needed to confirm these outcomes between the 2 ER techniques.
Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group
Husain, Aliya N. , Chapel, David B. , Attanoos, Richard , Beasley, Mary Beth , Butnor, Kelly J. , Đačić, Sanja , Hiroshima, Kenzo , Hung, Yin P. , Klebe, Sonja , Krausz, Thomas, Khoór, András , Litzky, Leslie A., Nabeshima, Kazuki , Roden, Anja C. , Roggli, Victor L., Schulte, Jefree J. , Sheaff, Michael , Walts, Ann E. , Colby, Thomas V. , Hung, Yin P , Brčić, Luka , Chirieac, Lucian R. , Churg, Andrew , Marchevsky, Alberto M. , Nicholson, Andrew G. , Pavlisko, Elizabeth N. , Sauter, Jennifer L. , Travis, William D. , Tsao, Ming‐Sound

Archives of Pathology & Laboratory Medicine | April 8, 2024 | Volume: 148 | Issue: 11 | Pages: 1251-1271

10.5858/arpa.2023-0304-ra | PMID 38586983 Get It

Context.— Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.— To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.— Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.— There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions.
Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy
Amrami, Abigail, Singh, Neha Atulkumar , Ali, Farwa , Pham, Nha Trang Thu, Stephens, Yehkyoung C. , Josephs, Keith A. , Whitwell, Jennifer L. , Singh, Neha Atulkumar

Movement Disorders | April 8, 2024 | Volume: 39 | Issue: 8 | Pages: 1402-1407

10.1002/mds.29806 | PMID 38586905 Get It

AbstractBackgroundMidbrain atrophy is a characteristic feature of progressive supranuclear palsy (PSP), observed in PSP‐Richardson's syndrome (PSP‐RS) and to a lesser extent PSP‐parkinsonism (PSP‐P).ObjectiveOur aim was to critically evaluate the utility of manual magnetic resonance imaging measurements of the midbrain tectal plate as a diagnostic biomarker in PSP.MethodsLength of the tectal plate and width of the superior and inferior colliculi were measured in 40 PSP (20 PSP‐RS and 20 PSP‐P) patients and compared with 20 Parkinson's disease and 20 healthy control subjects.ResultsTectal plate length was reduced in both PSP groups compared with Parkinson's disease and control subjects and was most abnormal in PSP‐RS followed by PSP‐P. Reduced tectal plate length was associated with worse PSP Rating Scale scores.ConclusionsSimple manual measurements of tectal plate length show utility as a diagnostic biomarker in PSP, particularly for PSP‐RS.